{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T13:47:08Z","timestamp":1792504028451,"version":"4.5.0"},"reference-count":73,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,5,15]],"date-time":"2027-05-15T00:00:00Z","timestamp":1810339200000},"content-version":"am","delay-in-days":379,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K15079"],"award-info":[{"award-number":["23K15079"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.cld.2026.01.010","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T21:37:27Z","timestamp":1774388247000},"page":"495-511","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Metabolic Dysfunction-Associated Steatotic Liver Disease in Asia: Epidemiology, Clinical Features, and Management"],"prefix":"10.1016","volume":"30","author":[{"given":"Takashi","family":"Kobayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Yoneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Duseja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Gao","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Nersesov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cld.2026.01.010_bib1","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2026.01.010_bib2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.01.010_bib3","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1007\/s10620-016-4095-4","article-title":"Natural history of nonalcoholic fatty liver disease","volume":"61","author":"Goh","year":"2016","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cld.2026.01.010_bib4","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1016\/j.jhep.2023.12.030","article-title":"Almost identical values of various non-invasive indexes for hepatic fibrosis and steatosis between NAFLD and MASLD in Asia","volume":"80","author":"Nakano","year":"2024","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2026.01.010_bib5","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3350\/cmh.2023.0515","article-title":"Prognosis of biopsy-confirmed metabolic dysfunction- associated steatotic liver disease: a sub-analysis of the CLIONE study","volume":"30","author":"Iwaki","year":"2024","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.cld.2026.01.010_bib6","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.01.010_bib7","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.jceh.2021.11.010","article-title":"Prevalence of non-alcoholic fatty liver disease in India: a systematic review and meta-analysis","volume":"12","author":"Shalimar","year":"2022","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.cld.2026.01.010_bib8","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030","volume":"69","author":"Estes","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2026.01.010_bib9","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/apt.15673","article-title":"Modelling NAFLD disease burden in four Asian regions-2019-2030","volume":"51","author":"Estes","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cld.2026.01.010_bib10","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1089\/met.2021.0104","article-title":"Clinicopathological profile and outcome of a large cohort of patients with nonalcoholic fatty liver disease from South Asia: interim results of the Indian Consortium on Nonalcoholic Fatty Liver Disease","volume":"20","author":"Duseja","year":"2022","journal-title":"Metab Syndr Relat Disord"},{"key":"10.1016\/j.cld.2026.01.010_bib11","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/cld.1141","article-title":"Nonalcoholic fatty liver disease: indian perspective","volume":"18","author":"De","year":"2021","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.cld.2026.01.010_bib12","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2017.06.003","article-title":"New trends on obesity and NAFLD in Asia","volume":"67","author":"Fan","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2026.01.010_bib13","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/MD.0b013e3182779d49","article-title":"Nonalcoholic fatty liver disease in lean individuals in the United States","volume":"91","author":"Younossi","year":"2012","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.cld.2026.01.010_bib14","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hep4.1124","article-title":"Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: a long-term follow-up study","volume":"2","author":"Hagstr\u00f6m","year":"2018","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.cld.2026.01.010_bib15","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S2468-1253(20)30077-7","article-title":"Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"5","author":"Ye","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2026.01.010_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154911","article-title":"Non-obese non-alcoholic fatty liver disease (NAFLD) in Asia: an international registry study","volume":"126","author":"Tan","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.cld.2026.01.010_bib17","doi-asserted-by":"crossref","DOI":"10.1111\/liv.16123","article-title":"Global epidemiological impact of PNPLA3 I148M on liver disease","volume":"45","author":"Kozlitina","year":"2025","journal-title":"Liver Int"},{"key":"10.1016\/j.cld.2026.01.010_bib18","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat Genet"},{"key":"10.1016\/j.cld.2026.01.010_bib19","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/nature15394","article-title":"An integrated map of structural variation in 2,504 human genomes","volume":"526","author":"Sudmant","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.cld.2026.01.010_bib20","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41586-023-06045-0","article-title":"A genomic mutational constraint map using variation in 76,156 human genomes","volume":"625","author":"Chen","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.cld.2026.01.010_bib21","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.1038\/ncomms5309","article-title":"TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease","volume":"5","author":"Liu","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.cld.2026.01.010_bib22","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/ng.2901","article-title":"Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease","volume":"46","author":"Kozlitina","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.cld.2026.01.010_bib23","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/ng.2926","article-title":"Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk","volume":"46","author":"Holmen","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.cld.2026.01.010_bib24","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.gtc.2019.09.001","article-title":"Genetic risk factors and disease modifiers of nonalcoholic steatohepatitis","volume":"49","author":"Kozlitina","year":"2020","journal-title":"Gastroenterol Clin North Am"},{"key":"10.1016\/j.cld.2026.01.010_bib25","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMoa1712191","article-title":"A protein-truncating HSD17B13 variant and protection from chronic liver disease","volume":"378","author":"Abul-Husn","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cld.2026.01.010_bib26","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/apt.17292","article-title":"Review article: the role of HSD17B13 on global epidemiology, natural history, pathogenesis and treatment of NAFLD","volume":"57","author":"Amangurbanova","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cld.2026.01.010_bib27","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2217543120","article-title":"Inhibition of HSD17B13 protects against liver fibrosis by inhibition of pyrimidine catabolism in nonalcoholic steatohepatitis","volume":"120","author":"Luukkonen","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cld.2026.01.010_bib28","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12916-022-02716-3","article-title":"Lean or diabetic subtypes predict increased all-cause and disease-specific mortality in metabolic-associated fatty liver disease","volume":"21","author":"Chung","year":"2023","journal-title":"BMC Med"},{"key":"10.1016\/j.cld.2026.01.010_bib29","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up","volume":"61","author":"Ekstedt","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.01.010_bib30","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1136\/gutjnl-2020-322786","article-title":"Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort","volume":"70","author":"Simon","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.cld.2026.01.010_bib31","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1053\/j.gastro.2018.04.034","article-title":"Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study","volume":"155","author":"Vilar-Gomez","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2026.01.010_bib32","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3350\/cmh.2023.0485","article-title":"Global incidence of adverse clinical events in non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"30","author":"Le","year":"2024","journal-title":"Clin Molecular Hepatol"},{"key":"10.1016\/j.cld.2026.01.010_bib33","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0140-6736(03)15268-3","article-title":"Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies","volume":"363","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.cld.2026.01.010_bib34","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.01.010_bib35","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s12072-024-10774-3","article-title":"The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease","volume":"19","author":"Eslam","year":"2025","journal-title":"Hepatol Int"},{"key":"10.1016\/j.cld.2026.01.010_bib36","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.01.010_bib37","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD","volume":"45","author":"Angulo","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.01.010_bib38","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/hepr.13737","article-title":"Comparison of diagnostic performance between FIB-4 and NFS in metabolic-associated fatty liver disease era","volume":"52","author":"Park","year":"2022","journal-title":"Hepatol Res"},{"key":"10.1016\/j.cld.2026.01.010_bib39","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.29568","article-title":"Diagnostic performance of the fibrosis-4 index and nonalcoholic fatty liver disease fibrosis score in lean adults with nonalcoholic fatty liver disease","volume":"6","author":"Park","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.cld.2026.01.010_bib40","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/apt.17891","article-title":"Machine learning improves the prediction of significant fibrosis in Asian patients with metabolic dysfunction-associated steatotic liver disease: the Gut and Obesity in Asia (GO-ASIA) Study","volume":"59","author":"Verma","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cld.2026.01.010_bib41","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1053\/j.gastro.2004.11.018","article-title":"Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C","volume":"128","author":"Cast\u00e9ra","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2026.01.010_bib42","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/hep.23312","article-title":"Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease","volume":"51","author":"Wong","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.01.010_bib43","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/hepr.13871","article-title":"Diagnostic accuracy of enhanced liver fibrosis test for nonalcoholic steatohepatitis-related fibrosis: multicenter study","volume":"53","author":"Seko","year":"2023","journal-title":"Hepatol Res"},{"key":"10.1016\/j.cld.2026.01.010_bib44","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/hepr.13495","article-title":"Accuracy of the enhanced liver fibrosis test, and combination of the enhanced liver fibrosis and non-invasive tests for the diagnosis of advanced liver fibrosis in patients with non-alcoholic fatty liver disease","volume":"50","author":"Inadomi","year":"2020","journal-title":"Hepatol Res"},{"key":"10.1016\/j.cld.2026.01.010_bib45","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1111\/jgh.14156","article-title":"Wisteria floribunda agglutinin-positive Mac-2-binding protein and type 4 collagen 7S: useful markers for the diagnosis of significant fibrosis in patients with non-alcoholic fatty liver disease","volume":"33","author":"Ogawa","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2026.01.010_bib46","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s00535-024-02179-8","article-title":"Utility of mac-2 binding protein glycosylation isomer as an excellent biomarker for the prediction of liver fibrosis, activity, and hepatocellular carcinoma onset: an expert review","volume":"60","author":"Kamada","year":"2025","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.cld.2026.01.010_bib47","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/hepr.13857","article-title":"Meta-analysis of the diagnostic accuracy of serum type IV collagen 7S concentration for the staging of liver fibrosis in nonalcoholic fatty liver disease","volume":"53","author":"Honda","year":"2023","journal-title":"Hepatol Res"},{"key":"10.1016\/j.cld.2026.01.010_bib48","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-22767-z","article-title":"A 3-step approach to predict advanced fibrosis in nonalcoholic fatty liver disease: impact on diagnosis, patient burden, and medical costs","volume":"12","author":"Kobayashi","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.cld.2026.01.010_bib49","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.jhep.2024.10.015","article-title":"A metabolome-derived score predicts metabolic dysfunction-associated steatohepatitis and mortality from liver disease","volume":"82","author":"Huang","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2026.01.010_bib50","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1093\/ajcn\/nqab392","article-title":"Adiposity, metabolomic biomarkers, and risk of nonalcoholic fatty liver disease: a case-cohort study","volume":"115","author":"Pang","year":"2022","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.cld.2026.01.010_bib51","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.cgh.2020.12.016","article-title":"Direct comparison of US and MR elastography for staging liver fibrosis in patients with nonalcoholic fatty liver disease","volume":"20","author":"Imajo","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2026.01.010_bib52","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1053\/j.gastro.2015.11.048","article-title":"Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography","volume":"150","author":"Imajo","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2026.01.010_bib53","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S2468-1253(22)00124-8","article-title":"Global, regional, and national burden of hepatitis B, 1990-2019: a systematic analysis for the global burden of disease study 2019","volume":"7","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2026.01.010_bib54","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1111\/liv.15131","article-title":"Progress towards achieving viral hepatitis B and C elimination in the Asia and Pacific region: results from modelling and global reporting","volume":"42","author":"Le","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.cld.2026.01.010_bib55","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/hep.32792","article-title":"Steatosis, HBV-related HCC, cirrhosis, and HBsAg seroclearance: a systematic review and meta-analysis","volume":"77","author":"Mao","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.01.010_bib56","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.cgh.2024.01.045","article-title":"Chronic viral hepatitis B and C outweigh MASLD in the associated risk of cirrhosis and HCC","volume":"22","author":"Lee","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2026.01.010_bib57","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.jhep.2018.08.011","article-title":"Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease","volume":"69","author":"Wong","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2026.01.010_bib58","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1136\/gutjnl-2020-323106","article-title":"Effect of green-Mediterranean diet on intrahepatic fat: the DIRECT PLUS randomised controlled trial","volume":"70","author":"Yaskolka","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.cld.2026.01.010_bib59","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cld.2026.01.010_bib60","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cld.2026.01.010_bib61","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/hep.31843","article-title":"Saroglitazar, a PPAR-\u03b1\/\u03b3 agonist, for treatment of NAFLD: a randomized controlled double-blind phase 2 trial","volume":"74","author":"Gawrieh","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.01.010_bib62","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-083735","article-title":"Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial","volume":"389","author":"Lin","year":"2025","journal-title":"BMJ"},{"key":"10.1016\/j.cld.2026.01.010_bib63","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/MEG.0000000000002517","article-title":"Statin can reduce the risk of hepatocellular carcinoma among patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"35","author":"Zhang","year":"2023","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2026.01.010_bib64","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13520","article-title":"Obesity in South and Southeast Asia-A new consensus on care and management","volume":"24","author":"Tham","year":"2023","journal-title":"Obes Rev"},{"key":"10.1016\/j.cld.2026.01.010_bib65","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s13679-023-00507-2","article-title":"Bariatric and metabolic surgery and medical insurance payment in China","volume":"12","author":"Liang","year":"2023","journal-title":"Curr Obes Rep"},{"key":"10.1016\/j.cld.2026.01.010_bib66","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/j.jhep.2025.03.005","article-title":"Underrepresentation of Asians in diagnostic test development and drug trials in MASLD","volume":"83","author":"Mak","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2026.01.010_bib67","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cld.2026.01.010_bib68","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1111\/hepr.13688","article-title":"Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis 2020","volume":"51","author":"Tokushige","year":"2021","journal-title":"Hepatol Res"},{"key":"10.1016\/j.cld.2026.01.010_bib69","first-page":"955","article-title":"Guideline for the prevention and treatment of Metabolic dysfunction-associated Fatty liver disease (version 2024)","volume":"12","author":"Fan","year":"2024","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.cld.2026.01.010_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.jceh.2025.102590","article-title":"Adoption of the new nomenclature of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) by the Indian National Association for Study of the Liver (INASL): implications for the INASL guidance paper on NAFLD","volume":"15","author":"Duseja","year":"2025","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.cld.2026.01.010_bib71","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000571","article-title":"Clinical care guidance in patients with diabetes and metabolic dysfunction-associated steatotic liver disease: a joint consensus","volume":"8","author":"Huang","year":"2024","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.cld.2026.01.010_bib72","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/jgh.15787","article-title":"Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction-associated fatty liver disease","volume":"37","author":"Chan","year":"2022","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2026.01.010_bib73","doi-asserted-by":"crossref","first-page":"929","DOI":"10.12669\/pjms.41.3.10081","article-title":"HEPNET position Statement-I, case definition, classification, screening & diagnosis of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Pakistan: a resource for primary and secondary care physicians","volume":"41","author":"Ali","year":"2025","journal-title":"Pak J Med Sci"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326126000103?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326126000103?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T20:57:33Z","timestamp":1778878653000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326126000103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":73,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1089326126000103"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2026.01.010","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolic Dysfunction-Associated Steatotic Liver Disease in Asia: Epidemiology, Clinical Features, and Management","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2026.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}